miR-103a-3p alleviates oxidative stress, apoptosis, and immune disorder in oxygen-glucose deprivation-treated BV2 microglial cells and rats with cerebral ischemia-reperfusion injury by targeting high mobility group box 1

Abstract

HMGB1 is targeted by miR-103a-3p, which may be a new strategy in the treatment of CI/R.